This trial is testing magrolimab in combination with mogamulizumab to see if it can help patients with T-cell lymphoma that has come back or does not respond to treatment. Magrolimab and mogamulizumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread.
- Mycosis Fungoides
- Mycosis Fungoides and Sezary Syndrome
- Sezary Syndrome
- Cutaneous T-Cell Lymphoma
2 Primary · 6 Secondary · Reporting Duration: Up to 2 years
Side Effects for
Awards & Highlights
2 Treatment Groups
Arm II (mogamulizumab), Phase II
1 of 2
Arm I (magrolimab, mogamulizumab), Phase Ib and Phase II
1 of 2
88 Total Participants · 2 Treatment Groups
Primary Treatment: Magrolimab · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- 2020. "Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04541017.
Frequently Asked Questions
What objectives do investigators hope to meet with this experiment?
"This trial will evaluate the primary outcome of Overall Response Rate at 6 months (ORR6) over a period spanning 4 weeks from receiving the initial magrolimab infusion. Secondary outcomes include ORR12, defined by patients having a partial or complete response for 12+ months; ORR, marked by global response score; and PFS observed through Kaplan-Meier method and log-rank test." - Anonymous Online Contributor
What is the upper limit of participants involved in this research?
"Yes, the information provided on clinicaltrials.gov confirms that recruitment for this trial is still underway. Initially posted in December 2020 and last updated in November 2022, it requires 88 participants to be recruited at two separate sites." - Anonymous Online Contributor
Are there other precedents for Magrolimab's efficacy in clinical testing?
"Magrolimab was first studied in 2013 at Aichi Medical University, with 80 concluded trials and 25 presently active ones. Most of these current studies are being conducted from a medical facility located in Duarte, California." - Anonymous Online Contributor
Is enrollment open for this investigational study?
"According to clinicaltrials.gov, the recruitment process for this medical study is ongoing; it was initially published on December 24th 2020 and last updated on November 10th 2022." - Anonymous Online Contributor